CLINICAL TRIALS PROFILE FOR CIRAPARANTAG
✉ Email this page to a colleague
Clinical Trials for Ciraparantag
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT01826266 ↗ | Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban | Completed | Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | Phase 1 | PER977 monotherapy and co-administration following 60 mg edoxaban will have an acceptable safety and tolerability profile with no impact on pro-coagulant biomarkers. A dose of PER977 that reverses the effects of edoxaban on the pharmacodynamic (PD) biomarkers (point of care prothrombin time [PoC-PT]), and/or secondary biomarkers (thromboelastography reaction time [TEG-R]) will be identified. |
| NCT01826266 ↗ | Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban | Completed | Perosphere, Inc. | Phase 1 | PER977 monotherapy and co-administration following 60 mg edoxaban will have an acceptable safety and tolerability profile with no impact on pro-coagulant biomarkers. A dose of PER977 that reverses the effects of edoxaban on the pharmacodynamic (PD) biomarkers (point of care prothrombin time [PoC-PT]), and/or secondary biomarkers (thromboelastography reaction time [TEG-R]) will be identified. |
| NCT03172910 ↗ | Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT | Completed | Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | Phase 2 | This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with rivaroxaban measuring clotting times using Whole Blood Clotting Time (WBCT). |
| NCT03172910 ↗ | Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT | Completed | Perosphere, Inc. | Phase 2 | This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with rivaroxaban measuring clotting times using Whole Blood Clotting Time (WBCT). |
| NCT03288454 ↗ | Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT | Completed | Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | Phase 2 | This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with apixaban measuring clotting times using Whole Blood Clotting Time (WBCT). |
| NCT03288454 ↗ | Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT | Completed | Perosphere, Inc. | Phase 2 | This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with apixaban measuring clotting times using Whole Blood Clotting Time (WBCT). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Ciraparantag
Condition Name
Clinical Trial Locations for Ciraparantag
Trials by Country
Clinical Trial Progress for Ciraparantag
Clinical Trial Phase
Clinical Trial Sponsors for Ciraparantag
Sponsor Name
